Genetic Variants Associated With Adolescent Suicide Attempts

Attempt Suicide Clinical Trial

— VGTSA  

Official title:

Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02001649
• Other study ID #: 2013/092/HP
• Status: Completed
• Phase: N/A
• First received: November 14, 2013
• Last updated: October 7, 2016
• Start date: December 2013
• Est. completion date: July 2016

Study information

• Verified date: October 2016
• Source: University Hospital, Rouen
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Suicidal behaviors is known to aggregate in families. The purpose of this study is to evaluate association between common polymorphisms in genes important for neurobiological pathways linked to suicidal behaviors and suicide attempt among adolescents patient.

Description:

In France, suicide is the second leading cause of death among the 14-22 years population. Suicide behavior (SB) spans a spectrum ranging from suicidal ideation to suicide attempts and completed suicide. Several factors likely determine the predisposition to SB, including biological factors and psychosocial stressors. For biological factors, convergent evidence from adoption, family, and twin studies of suicide strongly suggests genetic contributions to liability for SB. Although genetic factors play a role in SB, identifying specific genes involved has proved challenging. Molecular-genetic technologies have made great advances in the past decade, including genome- wide searches for disease-causing genes with the linkage disequilibrium (LD) approach. Despite being a major public health problem in the youth population, genetic associations studies regarding suicidal behavior in adolescence are still rare. Genes that code for proteins involved in regulating serotonergic neurotransmission have thus been major candidate genes for association studies of SB. Among them, genes for serotonin metabolism (tryptophan hydroxylase, TPH), serotonin transport (5-HTT), and the serotonergic 2A (5-HT2A) receptor have received the most research attention.

The identification of relevant genetic variants or SNPs in others genes which are involved in the neurobiological pathways (which the alteration may contribute to a suicidal behavior) can help not only to advance knowledge of the genetic bases of suicide but also to identify new therapeutic targets.

On the basis of review of the literature, investigators will identify candidate genes that have been reported to be associated with suicidal events.

The investigators will target genes related to central serotonergic and noradrenergic neurotransmission, and monoamine metabolism (MAOA). The investigators will also study genes involved in glutamatergic neurotransmission (GRIK2, GRIA3) and in the HPA axis (FKBP5) and genes that code for neurotrophic proteins (BDNF).

DNA will be obtained from saliva. All genotyping will be carried out using standard polymerase chain reaction-based techniques that are routinely used in the Human Genetics Laboratory. DNA segments containing the target variable site will be amplified using unique sequence flanking primers.

Tests of association between genetic variant and suicide attempt will be conducted using Chi squared and Armitage Trend Tests. Logistical regression analyses will be performed to evaluate the contribution of individual genetic variant to the prediction of suicide attempt, and to examine SNPs for potential gene-gene and gene-environment interactions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 13 Years to 17 Years

Eligibility

Inclusion Criteria:

Case :

• Age at admission between 13 and 17 years old

• Hospitalized for attempted suicide

• Absence of prominent mental retardation or organic brain damage

• Fluent in French

• Able to comprehend the study procedures and to undergo entry assessments safely

• Provided written informed consent for study participation, and additional consent from the patient's parents or guardians

• Northern and Western European ancestry (HapMap-CEU)

• Medical insurance coverage

Control :

• Healthy adult volunteers

• No present or past psychiatric illness

• No personal history of suicidal behavior and without a family history of suicide

• Provided written informed consent for study participation

• Northern or Western European ancestry (HapMap-CEU)

• Medical insurance coverage

Exclusion Criteria:

Case:

• Inability to get an informed and valid consent

• Home address outside the selected hospitals' geographic areas

• Intellectual disability or organic brain damage

• Origine ethnique non CEU

• Absence of medical insurance coverage

• Pregnant or lactating women

• Without Northern or Western European ancestry (HapMap-CEU)

Control :

• Inability to get an informed and valid consent

• Intellectual disability or organic brain damage

• History of suicidal behavior

• Psychiatric disorder, past or present

• Family history of suicide

• Borderline personality disorder

• Absence of medical insurance coverage

• Pregnant or lactating women

• Without Northern or Western European ancestry (HapMap-CEU)

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening

Related Conditions & MeSH terms

• Attempt Suicide
• Suicide
• Suicide, Attempted

Intervention

Genetic:
• SNP Genotyping
Individuals were genotyped at a total 96 SNP from 15 candidate gene
• SNP genotyping

Locations

Country	Name	City	State
France	Chu Rouen	Rouen	Haute Normandie

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Rouen	Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Odds ratio (OR) and 95% confidence interval (CI) will be estimated using a logistic regression model to assessing the contribution of each polymorphism as a risk factor in predicting suicidal behavior	Measure is a composite outcome measure consisting of multiple measures; Post hoc Bonferroni correction will be employed to correct for multiple testing.; Chi- square test will performed to analyze genetic associations	Between day 1 and day 5 during hospitalization	No